(WINT)

Role: 10%+ Owner
Signature: /s/ Lin, Jung-Chin
Issuer symbol: WINT
Transactions as of: 20 May 2020
Net transactions value: -$1,582,544
Form type: 4
Filing time: 10 Jan 2022, 16:03:07 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	WINT	Common Stock	Other	$0	-3,551,750	-75%	$0.000000	1,183,916	20 May 2020	Direct	F1, F2
transaction	WINT	Common Stock	Purchase	$399,997	+55,172	+4.7%	$7.25	1,239,088	20 May 2020	Direct	F2
transaction	WINT	Common Stock	Sale	$1,982,541	-1,239,088	-100%	$1.60	0	30 Dec 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	WINT	SERIES F WARRANTS	Other	$0	0		$0.000000^*	0	24 Jun 2020	Common Stock	384,824	$3.68	Direct	F4
transaction	WINT	SERIES G WARRANTS	Other	$0	-249,004	-50%	$0.000000	249,004	20 May 2020	Common Stock	249,004	$12.15	Direct	F5, F6
transaction	WINT	SERIES J WARRANTS	Purchase	$0	+55,172		$0.000000	55,172	20 May 2020	Common Stock	55,172	$7.98	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Bioengine Capital Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The Reporting Person voluntarily discloses that, on May 20, 2020, the Issuer effected a 1-for-3 reverse stock split of its Common Stock (the "Reverse Stock Split"), which resulted in the Reporting Person's ownership of issued and outstanding Common Stock being reduced from 3,551,750 shares of Common Stock to 1,183,916 shares of Common Stock.
F2	The shares were directly held by the Reporting Person and indirectly held by Center Laboratories, Inc., which owns 58.6% of the Reporting Person.
F3	On December 30, 2021, the Reporting Person sold all its remaining shares of Common Stock to Center Laboratories, Inc., which owns 58.6% of the Reporting Person. As a result of the foregoing transaction, the Reporting Person now directly owns 0 shares of Common Stock.
F4	The Reporting Person voluntarily discloses that, on July 24, 2020, Series F Warrants had expired. As a result, the Reporting Person now directly owns 0 shares of Series F Warrants.
F5	The Reporting Person voluntarily discloses that, on May 20, 2020, in connection with the Reverse Stock Split, the Issuer effected a 1-for-3 reverse split of all of its issued and outstanding Series G Warrants, which resulted in the Reporting Person's ownership of Series G Warrants being reduced from 747,012 shares of Series G Warrants to 249,004 shares of Series G Warrants.
F6	The exercise of the Series G Warrants is subject to a beneficial ownership limitation of 9.99% and this limitation can only be changed with effect from the 61st day after a notice requesting such change is delivered to the Issuer.

Remarks:

This filing constitutes a Form 4 exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended, as a result of the transactions reported herein.